Cyclacel Pharmaceuticals, Inc. (BGMS)
NASDAQ
Cyclacel Pharmaceuticals, Inc. Operating Income 2024–2025
Cyclacel Pharmaceuticals, Inc. annual/quarterly operating income history and growth rate from 2024 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Cyclacel Pharmaceuticals, Inc. operating income for the quarter ending March 31, 2026 was -246000, a 95.12% decrease year-over-year.
- Cyclacel Pharmaceuticals, Inc. operating income for the twelve months ending March 31, 2026 was -3.6 M.
- Cyclacel Pharmaceuticals, Inc. annual operating income for 2025 was -8.4 M, a 29.80% decrease from 2024.
- Cyclacel Pharmaceuticals, Inc. annual operating income for 2024 was -12.0 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Cyclacel Pharmaceuticals, Inc. Operating Income — FAQ
Cyclacel Pharmaceuticals, Inc. (BGMS) operating income over the last 2 years — annual and quarterly figures with year-over-year growth and charts.
What is Cyclacel Pharmaceuticals, Inc.'s operating income?
Cyclacel Pharmaceuticals, Inc. (BGMS) reported operating income of -$8M for fiscal 2025.
Where can I see BGMS's operating income history?
The chart and table above show Cyclacel Pharmaceuticals, Inc.'s operating income by year and by quarter, including the growth rate.